Treatment Alternative and High Safety Profile of Acupuncture Plus Chemotherapy for Advanced Gastric Cancer
Objective. The aim of this study is to evaluate the safety and tumor marker level changes of acupuncture plus chemotherapy (FOLFOX4) for advanced gastric cancer. Methods. One hundred and twenty patients with advanced gastric cancer who were treated at our hospital between May 2019 and April 2021 wer...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2022-07, Vol.2022, p.1-5 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2022 |
| creator | Miao, Xiaomei Wu, Hongying Liu, Yan Zhang, Shu Li, Chaohui Hao, Jie |
| description | Objective. The aim of this study is to evaluate the safety and tumor marker level changes of acupuncture plus chemotherapy (FOLFOX4) for advanced gastric cancer. Methods. One hundred and twenty patients with advanced gastric cancer who were treated at our hospital between May 2019 and April 2021 were recruited for prospective analysis, and all patients were allocated to the control and experimental groups in a 1 : 1 ratio using the random number table method, with 60 patients in each group. They received either chemotherapy using the FOLFOX4 regimen (control group) or the FOLFOX4 chemotherapy plus acupuncture (experimental group). Outcome measures included tumor marker levels, quality of life, and adverse events. Results. Before treatment, the two groups showed similar tumor markers levels and the MOS 36-item short-form health survey (SF-36) scores (P>0.05). FOLFOX4 chemotherapy plus acupuncture was associated with significantly lower levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA72-4 versus FOLFOX4 chemotherapy alone (P |
| doi_str_mv | 10.1155/2022/8701779 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9356787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2700312229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-29fe7c2a31987941c4d00ef3bb65b20f260feb74d8576282d1315bd4fd908a5a3</originalsourceid><addsrcrecordid>eNp90U9rHCEYBnApLU2a5NYPIPRSSDfxzziOl8KytEkh0EATyE0cfc24zIxbdbbst-8suwTaQ04q_njw9UHoIyVXlApxzQhj140kVEr1Bp1SWdFFxZrm7ctePp2gDzmvCWFKSvkenXChKsalOEXrhwSmDDAWvOwLpNGUsAVsRodvw3OHfxkPZYfvU_ShBxw9XtppM422TAnwfT9lvOpgiKWDZDY77GPCS7c1owWHb0wuKVi82h_TOXrnTZ_h4rieocfv3x5Wt4u7nzc_Vsu7heVClAVTHqRlhlPVSFVRWzlCwPO2rUXLiGc18dDKyjVC1qxhjnIqWld5p0hjhOFn6OshdzO1Azg7z5ZMrzcpDCbtdDRB_3szhk4_x61WXNSykXPA52NAir8nyEUPIVvoezNCnLJmkhBOGWNqpp_-o-s4zZ_Yz6pWSlScs3pWXw7KpphzAv_yGEr0vkS9L1EfS5z55YF3YXTmT3hd_wWX-Zsn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2699543326</pqid></control><display><type>article</type><title>Treatment Alternative and High Safety Profile of Acupuncture Plus Chemotherapy for Advanced Gastric Cancer</title><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Miao, Xiaomei ; Wu, Hongying ; Liu, Yan ; Zhang, Shu ; Li, Chaohui ; Hao, Jie</creator><contributor>Wu, Xueliang ; Xueliang Wu</contributor><creatorcontrib>Miao, Xiaomei ; Wu, Hongying ; Liu, Yan ; Zhang, Shu ; Li, Chaohui ; Hao, Jie ; Wu, Xueliang ; Xueliang Wu</creatorcontrib><description>Objective. The aim of this study is to evaluate the safety and tumor marker level changes of acupuncture plus chemotherapy (FOLFOX4) for advanced gastric cancer. Methods. One hundred and twenty patients with advanced gastric cancer who were treated at our hospital between May 2019 and April 2021 were recruited for prospective analysis, and all patients were allocated to the control and experimental groups in a 1 : 1 ratio using the random number table method, with 60 patients in each group. They received either chemotherapy using the FOLFOX4 regimen (control group) or the FOLFOX4 chemotherapy plus acupuncture (experimental group). Outcome measures included tumor marker levels, quality of life, and adverse events. Results. Before treatment, the two groups showed similar tumor markers levels and the MOS 36-item short-form health survey (SF-36) scores (P>0.05). FOLFOX4 chemotherapy plus acupuncture was associated with significantly lower levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA72-4 versus FOLFOX4 chemotherapy alone (P<0.05). The patients who were given FOLFOX4 chemotherapy plus acupuncture showed significantly increased SF-36 scores versus monotherapy of the FOLFOX4 regimen (P<0.05). The joint therapy resulted in a significantly lower incidence of adverse events versus the monotherapy (P<0.05). Conclusion. Acupuncture plus chemotherapy using the FOLFOX4 regimen can effectively regulate the serum tumor marker levels of patients with advanced gastric cancer, with a high safety profile, which provides a viable treatment alternative.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2022/8701779</identifier><identifier>PMID: 35942375</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Acupuncture ; Adverse events ; Anemia ; Antigens ; Biomarkers ; Cancer therapies ; Carcinoembryonic antigen ; Chemotherapy ; Disease ; Gastric cancer ; Leukopenia ; Males ; Metastasis ; Nausea ; Patients ; Peripheral neuropathy ; Pharmaceuticals ; Quality of life ; Safety ; Tumor markers ; Tumors ; Vomiting</subject><ispartof>Evidence-based complementary and alternative medicine, 2022-07, Vol.2022, p.1-5</ispartof><rights>Copyright © 2022 Xiaomei Miao et al.</rights><rights>Copyright © 2022 Xiaomei Miao et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Xiaomei Miao et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-29fe7c2a31987941c4d00ef3bb65b20f260feb74d8576282d1315bd4fd908a5a3</citedby><cites>FETCH-LOGICAL-c355t-29fe7c2a31987941c4d00ef3bb65b20f260feb74d8576282d1315bd4fd908a5a3</cites><orcidid>0000-0001-5150-0505</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356787/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356787/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><contributor>Wu, Xueliang</contributor><contributor>Xueliang Wu</contributor><creatorcontrib>Miao, Xiaomei</creatorcontrib><creatorcontrib>Wu, Hongying</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Zhang, Shu</creatorcontrib><creatorcontrib>Li, Chaohui</creatorcontrib><creatorcontrib>Hao, Jie</creatorcontrib><title>Treatment Alternative and High Safety Profile of Acupuncture Plus Chemotherapy for Advanced Gastric Cancer</title><title>Evidence-based complementary and alternative medicine</title><description>Objective. The aim of this study is to evaluate the safety and tumor marker level changes of acupuncture plus chemotherapy (FOLFOX4) for advanced gastric cancer. Methods. One hundred and twenty patients with advanced gastric cancer who were treated at our hospital between May 2019 and April 2021 were recruited for prospective analysis, and all patients were allocated to the control and experimental groups in a 1 : 1 ratio using the random number table method, with 60 patients in each group. They received either chemotherapy using the FOLFOX4 regimen (control group) or the FOLFOX4 chemotherapy plus acupuncture (experimental group). Outcome measures included tumor marker levels, quality of life, and adverse events. Results. Before treatment, the two groups showed similar tumor markers levels and the MOS 36-item short-form health survey (SF-36) scores (P>0.05). FOLFOX4 chemotherapy plus acupuncture was associated with significantly lower levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA72-4 versus FOLFOX4 chemotherapy alone (P<0.05). The patients who were given FOLFOX4 chemotherapy plus acupuncture showed significantly increased SF-36 scores versus monotherapy of the FOLFOX4 regimen (P<0.05). The joint therapy resulted in a significantly lower incidence of adverse events versus the monotherapy (P<0.05). Conclusion. Acupuncture plus chemotherapy using the FOLFOX4 regimen can effectively regulate the serum tumor marker levels of patients with advanced gastric cancer, with a high safety profile, which provides a viable treatment alternative.</description><subject>Acupuncture</subject><subject>Adverse events</subject><subject>Anemia</subject><subject>Antigens</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Carcinoembryonic antigen</subject><subject>Chemotherapy</subject><subject>Disease</subject><subject>Gastric cancer</subject><subject>Leukopenia</subject><subject>Males</subject><subject>Metastasis</subject><subject>Nausea</subject><subject>Patients</subject><subject>Peripheral neuropathy</subject><subject>Pharmaceuticals</subject><subject>Quality of life</subject><subject>Safety</subject><subject>Tumor markers</subject><subject>Tumors</subject><subject>Vomiting</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp90U9rHCEYBnApLU2a5NYPIPRSSDfxzziOl8KytEkh0EATyE0cfc24zIxbdbbst-8suwTaQ04q_njw9UHoIyVXlApxzQhj140kVEr1Bp1SWdFFxZrm7ctePp2gDzmvCWFKSvkenXChKsalOEXrhwSmDDAWvOwLpNGUsAVsRodvw3OHfxkPZYfvU_ShBxw9XtppM422TAnwfT9lvOpgiKWDZDY77GPCS7c1owWHb0wuKVi82h_TOXrnTZ_h4rieocfv3x5Wt4u7nzc_Vsu7heVClAVTHqRlhlPVSFVRWzlCwPO2rUXLiGc18dDKyjVC1qxhjnIqWld5p0hjhOFn6OshdzO1Azg7z5ZMrzcpDCbtdDRB_3szhk4_x61WXNSykXPA52NAir8nyEUPIVvoezNCnLJmkhBOGWNqpp_-o-s4zZ_Yz6pWSlScs3pWXw7KpphzAv_yGEr0vkS9L1EfS5z55YF3YXTmT3hd_wWX-Zsn</recordid><startdate>20220730</startdate><enddate>20220730</enddate><creator>Miao, Xiaomei</creator><creator>Wu, Hongying</creator><creator>Liu, Yan</creator><creator>Zhang, Shu</creator><creator>Li, Chaohui</creator><creator>Hao, Jie</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5150-0505</orcidid></search><sort><creationdate>20220730</creationdate><title>Treatment Alternative and High Safety Profile of Acupuncture Plus Chemotherapy for Advanced Gastric Cancer</title><author>Miao, Xiaomei ; Wu, Hongying ; Liu, Yan ; Zhang, Shu ; Li, Chaohui ; Hao, Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-29fe7c2a31987941c4d00ef3bb65b20f260feb74d8576282d1315bd4fd908a5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acupuncture</topic><topic>Adverse events</topic><topic>Anemia</topic><topic>Antigens</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Carcinoembryonic antigen</topic><topic>Chemotherapy</topic><topic>Disease</topic><topic>Gastric cancer</topic><topic>Leukopenia</topic><topic>Males</topic><topic>Metastasis</topic><topic>Nausea</topic><topic>Patients</topic><topic>Peripheral neuropathy</topic><topic>Pharmaceuticals</topic><topic>Quality of life</topic><topic>Safety</topic><topic>Tumor markers</topic><topic>Tumors</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miao, Xiaomei</creatorcontrib><creatorcontrib>Wu, Hongying</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Zhang, Shu</creatorcontrib><creatorcontrib>Li, Chaohui</creatorcontrib><creatorcontrib>Hao, Jie</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miao, Xiaomei</au><au>Wu, Hongying</au><au>Liu, Yan</au><au>Zhang, Shu</au><au>Li, Chaohui</au><au>Hao, Jie</au><au>Wu, Xueliang</au><au>Xueliang Wu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment Alternative and High Safety Profile of Acupuncture Plus Chemotherapy for Advanced Gastric Cancer</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><date>2022-07-30</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Objective. The aim of this study is to evaluate the safety and tumor marker level changes of acupuncture plus chemotherapy (FOLFOX4) for advanced gastric cancer. Methods. One hundred and twenty patients with advanced gastric cancer who were treated at our hospital between May 2019 and April 2021 were recruited for prospective analysis, and all patients were allocated to the control and experimental groups in a 1 : 1 ratio using the random number table method, with 60 patients in each group. They received either chemotherapy using the FOLFOX4 regimen (control group) or the FOLFOX4 chemotherapy plus acupuncture (experimental group). Outcome measures included tumor marker levels, quality of life, and adverse events. Results. Before treatment, the two groups showed similar tumor markers levels and the MOS 36-item short-form health survey (SF-36) scores (P>0.05). FOLFOX4 chemotherapy plus acupuncture was associated with significantly lower levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA72-4 versus FOLFOX4 chemotherapy alone (P<0.05). The patients who were given FOLFOX4 chemotherapy plus acupuncture showed significantly increased SF-36 scores versus monotherapy of the FOLFOX4 regimen (P<0.05). The joint therapy resulted in a significantly lower incidence of adverse events versus the monotherapy (P<0.05). Conclusion. Acupuncture plus chemotherapy using the FOLFOX4 regimen can effectively regulate the serum tumor marker levels of patients with advanced gastric cancer, with a high safety profile, which provides a viable treatment alternative.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>35942375</pmid><doi>10.1155/2022/8701779</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-5150-0505</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2022-07, Vol.2022, p.1-5 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9356787 |
| source | Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Acupuncture Adverse events Anemia Antigens Biomarkers Cancer therapies Carcinoembryonic antigen Chemotherapy Disease Gastric cancer Leukopenia Males Metastasis Nausea Patients Peripheral neuropathy Pharmaceuticals Quality of life Safety Tumor markers Tumors Vomiting |
| title | Treatment Alternative and High Safety Profile of Acupuncture Plus Chemotherapy for Advanced Gastric Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A47%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20Alternative%20and%20High%20Safety%20Profile%20of%20Acupuncture%20Plus%20Chemotherapy%20for%20Advanced%20Gastric%20Cancer&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Miao,%20Xiaomei&rft.date=2022-07-30&rft.volume=2022&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2022/8701779&rft_dat=%3Cproquest_pubme%3E2700312229%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2699543326&rft_id=info:pmid/35942375&rfr_iscdi=true |